Filing a Timely Protest is Half the Battelle
Client Alert | 2 min read | 03.24.22
A difficult decision facing an offeror eliminated from a competition prior to award is when to be debriefed. FAR 15.505 instructs that an offeror eliminated from a competition must request a debriefing within three days of the notification of their elimination, but may choose to defer the actual debriefing until after an award is made. There is some facial appeal to that delay—more information may be available after the agency’s award decision. But GAO’s recent decision in Battelle Memorial Institute, B-420403, B-420403.2, B-420403.3, Mar. 10, 2022, highlights the risk of that delay: a protest being dismissed as filed too late.
Battelle involved a Navy procurement under FAR Part 36.6 seeking architect-engineering services in support of environmental cleanup efforts. Five offerors, including Battelle and Geosyntec Jacobs (“Jacobs”), each timely submitted a statement of qualification (“SF 330”). In April 2021, the Navy identified Jacobs as the highest qualified firm and opened negotiations pursuant to FAR 36.606(a). At this point, the Navy offered all unsuccessful offerors the option of receiving a pre-award debriefing or delaying the debriefing until after the Navy made its award decision. Battelle timely requested a pre-award debriefing, but then revised that request, and asked for a post-award debriefing instead. Seven months later, the Navy awarded the contract to Jacobs, and then provided Battelle with a written post-award debriefing.
One day after receiving its debriefing, Battelle protested the award at GAO. Battelle argued that the Navy unreasonably evaluated its SF 330 and that but for the Navy’s errors, Battelle, not Jacobs, would have been selected as the highest qualified firm. The Navy requested that Battelle’s protest be dismissed, arguing that it was based on information Battelle could have learned in a pre-award debriefing, and that Battelle did not diligently pursue its basis of protest when it voluntarily postponed its debriefing until after award.
GAO agreed with the Navy, and dismissed Battelle’s protest as untimely, applying the foundational principle that a protester must expeditiously gather all information available and then timely protest based on that information. GAO has repeatedly dismissed as untimely protests filed after a deferred debriefing, where the information would have been available in a pre-award debriefing. Although Battelle involved a procurement under FAR 36.6—as opposed to FAR Part 15, which contains the relevant agency debriefing obligations—GAO explained that the diligent pursuit obligation is universal. GAO held that because Battelle was challenging the Navy’s evaluation of Battelle’s SF 330 (as opposed to the ultimate award to Jacobs), a pre-award debriefing in April 2021 “would have been the most expeditious information-gathering approach available under these facts, as information regarding the agency’s evaluation of Battelle’s SF 330 would have likely been disclosed in a pre-award debriefing.” GAO concluded that by deferring its pre-award debriefing, Battelle had not met its diligent pursuit obligation.
While the takeaway from Battelle seems clear—take your debriefing as soon as it is offered, and assume your protest clock has begun to run as soon as the debriefing closes—questions around the time for filing a protest can be difficult. (We previously explained the risk of filing a protest too early). Fortunately, Crowell already has a tool to help answer those questions. Still, would-be protesters should engage with outside counsel early in the procurement process to ensure they understand the applicable protest-timing requirements, and the risks attendant to each.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection


